The PLG Business Development Awards are back live in 2022! Since their inception in 2007 the PLG BD Awards have showcased the best of deal-making in the healthcare industry, recognising individual contributions, upcoming talent and overall impact from deals completed during the year.

The 2022 awards will be held at 30 Euston Square (Royal College of General Practitioners), London, on Thursday 31 March 2022, with plenty of opportunities to network with friends and colleagues face to face throughout the event, including networking reception, ahead of the sit-down dinner and awards presentation.

We are delighted to be joined for the evening as our keynote speaker by Richard Westcott. Richard has worked as a journalist at the BBC for almost 20 years, becoming the Science and Technology Correspondent in Jan 2018.

Workshop 1 – Deal Watch Review of 2021
Presented by Sharon Finch & Jill Ogden

A regular feature at our awards event, Sharon and Jill will take a look at the significant deals that were concluded in 2021, to identify any overarching trends during the year. Where appropriate comparison will be made with previous years.

Workshop 2 – Market and Investor Insights
Presented by Nicholas Moore, Managing Director, Healthcare Investment Banking, Stifel

Our Speakers

Sharon Finch
Sharon has worked in business development for more than 40 years since joining the pharma industry in 1978. Her extensive experience was gained through roles in the Wellcome Foundation Ltd (Wellcome Research and Wellcome Diagnostics); Medeva plc and Ono Pharmaceutical Co. Ltd.  More recently Sharon ran the boutique BD consultancy company Medius Associates, where her projects included partnering assignments, due diligence exercises, valuations and BD training. 

In addition to her client work, Sharon has held posts at the Pharmaceutical Licensing Group including a past President of the European Pharmaceutical Licensing Group Council and former UK Chairman.

Sharon holds a BSc in Chemistry and Administration and studied for an MA in Business Law.

Jill Ogden
Jill has over 30 years of business development and R&D experience in the biopharmaceutical industry working both in-house and as a consultant at senior management and Board levels. During her career Jill has worked for numerous companies from small biotechs to mid-sized and large pharma. Jill has a successful deal track record including corporate and asset acquisitions and technology/product licensing transactions and her experience covers a wide range of therapeutic areas and technology platforms. She has a PhD in Genetics.

Nicholas Moore
Nicholas has over 20 years’ experience in the Healthcare industry, having originally trained as a medical doctor at Cambridge University and Harvard Medical School, following an undergraduate degree in Medical Sciences with a focus on immunology also at Cambridge.

Since mid-2013, Nicholas has focused on raising equity capital for European healthcare companies, especially those companies in the biopharma subsector targeting investment from U.S.-based healthcare specialist investors. In January 2018, Nicholas moved to Stifel as a Managing Director on the Healthcare Investment Banking team to continue to focus on delivering equity financing solutions to Europe-based healthcare companies, but also with a broader remit across M&A and strategic advice.